

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Taylor Daphne</u> (Last) (First) (Middle) <u>C/O APTEVO THERAPEUTICS INC.</u> <u>2401 4TH AVENUE, SUITE 1050</u> (Street) <u>SEATTLE WA 98121</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/03/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>Aptevo Therapeutics Inc. [APVO]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> Officer (give title below) <u>SVP, CFO</u> 10% Owner Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>3,840</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Restricted Stock Unit</u>	<u>(1)</u>	<u>(1)</u>	<u>Common Stock</u>	<u>792</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Unit</u>	<u>(3)</u>	<u>(3)</u>	<u>Common Stock</u>	<u>4,750</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Unit</u>	<u>(4)</u>	<u>(4)</u>	<u>Common Stock</u>	<u>13,889</u>	<u>(2)</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(5)</u>	<u>02/18/2030</u>	<u>Common Stock</u>	<u>2,400</u>	<u>6.97</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(6)</u>	<u>07/27/2030</u>	<u>Common Stock</u>	<u>514</u>	<u>8.56</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(6)</u>	<u>07/27/2030</u>	<u>Common Stock</u>	<u>514</u>	<u>8.56</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(6)</u>	<u>07/27/2030</u>	<u>Common Stock</u>	<u>516</u>	<u>8.56</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(6)</u>	<u>07/27/2030</u>	<u>Common Stock</u>	<u>839</u>	<u>8.56</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(7)</u>	<u>01/29/2031</u>	<u>Common Stock</u>	<u>7,125</u>	<u>33.5</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(8)</u>	<u>03/04/2032</u>	<u>Common Stock</u>	<u>4,750</u>	<u>5.3</u>	<u>D</u>	

Explanation of Responses:

- The Restricted Stock Units ("RSUs") vest in three approximately equal annual installments beginning on January 29, 2022. The RSUs were granted on January 29, 2021. As of the date of this filing, all but 792 shares had vested.
- Restricted Stock Units ("RSUs") convert into common stock, \$0.001 par value per share, of the Issuer on a one-for-one basis.
- The RSUs vest in three approximately equal annual installments beginning on March 4, 2023. The RSUs were granted on June 7, 2022.
- The RSUs vest in two approximately equal annual installments beginning the day immediately prior to the annual anniversary of the grant date. The RSUs were granted on August 9, 2022.
- The option vests in three approximately equal annual installments beginning on February 18, 2021. The option was granted on February 18, 2020.
- The option vests in three approximately equal annual installments beginning on July 27, 2021. The option was granted on July 27, 2020.
- The option vests in three approximately equal annual installments beginning on January 29, 2022. The option was granted on January 29, 2021.
- The option vests in three approximately equal annual installments beginning on March 4, 2023. The option was granted on March 4, 2022.

Remarks:

/s/ SoYoung Kwon,

Attorney-in-Fact

03/07/2023

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints SoYoung Kwon as his or her true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Aptevo Therapeutics Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder, and any other forms or reports the undersigned may be required to file in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or other form or report, and timely file such form or report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his or her discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Securities Exchange Act of 1934 and the rules thereunder, as amended.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 23rd day of January, 2023.

/s/ Daphne Taylor